News

Mason engineers and partners receive $3M award to build new technology for personalized musculoskeletal injury rehabilitation to support troop readiness

Musculoskeletal injury (MSKI) is the most common form of medical injury experienced by Service members. Clinical interventions for MSKIs lack objective measures to determine their effectiveness, putting affected military personnel at risk of further damage if they return to duty  before fully recovering.

George Mason University bioengineer Dr. Parag Chitnis, an associate professor in the Department of Bioengineering and a member of the Institute for Biohealth Innovation (IBI), and his team are developing quantitative assessments that can both prevent and monitor MSKIs in Service members.

In partnership with Cephasonics Ultrasound, an ultrasound systems and technology company in California, and Infinite Biomedical Technologies, a biotechnology company in Maryland, the team has been selected by the United States Army Medical Research and Development Command to receive nearly $3M from the United States Department of Defense, awarded through the Medical Technology Enterprise Consortium (MTEC). The award will support the team’s development of wearable, compact, and hands-free ultrasound systems to assess rehabilitation and recovery from MSKIs through measurements of muscle structure and function during physical activity, with a specific focus on knee injuries.

“MTEC aims to facilitate prototype advancement in support of the Warfighters’ MSKI needs, “ said Dr. Lauren Palestrini, MTEC’s chief science officer. “We are excited to issue this award to the team at George Mason University and believe it has the potential to make great strides in military health and ultrasound research.”

Prior to this award, Dr. Chitnis and Dr. Siddhartha Sikdar, a professor in the Department of Bioengineering and a member of the IBI, formed the Training and Recovery Augmented with Ultrasound Myography and Assessment (TRAUMA) program. With funding from the Department of Defense’s Military Operational Medicine Research Program, TRAUMA’s goal is to develop ultrasound systems that can be used to evaluate MSKIs in dynamic settings. The award from MTEC enables the team to further advance their ongoing research.

“The ability to objectively monitor both injury and the recovery process is key to the continued health of our Service men and women,” said Dr. Elizabeth Russell Esposito, the program area manager for Musculoskeletal Injury Treatment and Rehabilitation at the Military Operational Medicine Research Program. “The solutions that Dr. Chitnis and his team are developing will augment the existing capabilities of our clinical teams to support medical readiness.”

While ultrasound is the diagnostic standard for MSKIs, diagnostic criteria are based on subjective interpretation of images and greatly rely on an operator’s level of expertise and amount of training received. Additionally, bulky ultrasound probes are ill-suited for the continuous monitoring of muscles during physical movement. For example, their size frequently prevents probes from maintaining adequate skin contact and their position on the body while a patient is performing rehabilitation exercises. Dr. Chitnis and his team aim to address these limitations with their revolutionary approach.

The team plans to use wearable, miniaturized ultrasound sensors that can be adhered to the body like a bandage, making the technology hands-free. The sensors can connect to a smartphone or tablet and will work in tandem with two systems: motion mode and brightness mode. Motion mode imaging provides a one-dimensional view of an object, while brightness mode imaging produces a two-dimensional display. Through former research, Dr. Chitnis, Dr. Sikdar, and their teams have already created a motion-mode system. The brightness mode system will be fabricated with the help of Cephasonics Ultrasound.

“Cephasonics Ultrasound is thrilled to have the opportunity to contribute our ultrasound technology to help address the pressing needs of not only our military, but also of the broader rehabilitation field,” said Randall Whiting, chief operating officer of Cephasonics Ultrasound.

The project will be broken up into three parts. First, the team will interview civilian and active-duty military clinicians, as well as athletic trainers, to better understand the gaps in care for MSKIs and how their ultrasound systems can aid in filling them. Next, they will develop and refine the motion-mode and brightness-mode systems in order to optimize image quality, along with performing benchtop validation testing to ensure that the systems serve the needs of the user. Finally, the team will test their wearable ultrasound systems for selected clinical use cases.

The third step incorporates assistance from Dr. Margaret Jones, a professor in the School of Sport, Recreation, and Tourism Management and a member of the IBI. Dr. Jones, who specializes in sports medicine, physiotherapy, and MSKIs, is also the director of the Patriot Performance Lab. She will support the team in recruiting Mason athletes and carrying out preliminary testing.

Other Mason collaborators include Dr. Pilgyu Kang, an assistant professor in the Department of Mechanical Engineering and a member of the IBI, and Dr. Qi Wei, an associate professor in the Department of Bioengineering and a member of the IBI.

Amy Adams, executive director of the IBI, is proud of the multidisciplinary efforts taking place at Mason.

“By harnessing the extraordinary power of working across disciplines, our researchers are able to address complex health challenges through a unique lens,” said Adams. “Collaborations among our diverse research community are fundamental to delivering impactful scientific innovations.”

Dr. Chitnis remarked that he hopes the smaller ultrasound systems eventually can be deployed in remote locations, during routine physical training for military personnel, and in ambulances. Ultimately he would like to see the ultrasound technology expand for use in a range of medical ailments and emergencies in both civilian and military settings.

“I am constantly amazed with this team’s innovative spirit and their drive to make radical improvements in ultrasound sensing and imaging,” said Dr. Chitnis. “It’s an ambitious endeavor, but knowing the people involved, I am confident that we will see through our mission.”

The views expressed in this news release/article are those of the authors and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation